Table 4. Glycemic Control, Insulin Dose, and Cost in the MDI Subset.
| V-Go (n=95) | STO (n=113) | p-Value | |
| Baseline HbA1c, % | |||
| Mean (SD) | 9.9 (1.5) | 9.4 (1.3) | .005 |
| Change (EOS – baseline) HbA1c, % | |||
| Mean (SD) | -1.0 (1.6) | -0.36 (1.5) | .006 |
| Baseline TDD (U/day) | |||
| Mean (SD) | 75 (23.1) | 77 (27.3) | .624 |
| EOS TDD (U/day) | |||
| Mean (SD) | 55 (14.0) | 77 (28.2) | < .001 |
| EOS Diabetes treatment cost PPPD, $ | |||
| Mean (SD) | 30.59 (17.6) | 32.20 (32.4) | .006 |
| EOS Diabetes treatment cost effectiveness, $ cost per 1% HbA1c dropa | |||
| Mean | 24.02 | 58.86 |
EOS: end of study; HbA1c: glycated hemoglobin; MDI: multiple daily insulin injection; PPPD: per patient per day; SD: standard deviation; STO: standard treatment optimized; TDD: total daily dose; a Cost ($) of diabetes treatment per 1% drop in HbA1c was calculated based on the sample means: WAC costs for all diabetes treatments divided by mean change in HbA1c. Therefore, SD and p-Value were not calculated.